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Forkhead box (Fox) proteins are an extensive family of transcrip-
tion factors, which play a key role in the regulation of crucial
biological processes, including cell proliferation, differentiation,
metabolism, tissue homeostasis, senescence, survival, apoptosis,
and DNA damage repair (1). The unifying feature of Fox pro-
teins is the “forkhead” box, a sequence of about 100 amino acids
that enables binding to specific DNA sequences. The forkhead
motif is also known as a “winged-helix” DNA binding domain
(DBD) because of its distinct butterfly like appearance. The found-
ing Fox member was first identified in the fruitfly (Drosophilia
Melanogaster) over 20 years ago, when mutation of the fork head
(fkh) gene in these flies was found to result in fork-patterned
embryo heads. To date, over 50 mammalian Fox proteins have
been identified, and further divided into 19 subclasses (FoxA to
FoxS) based on their protein sequence homology. These Fox pro-
teins rely on precise temporal and spatial controls to directly affect
crucial cell fate decisions, regulating gene networks involved in
cell cycle progression, proliferation, survival, and differentiation.
Hence, not unexpectedly, defects in the regulation or deregulation
of their activity can lead to profound consequences, such as cancer
initiation and progression.
The best-studied Fox proteins involved in cancer are FoxO3a,
FoxM1, and FoxA1 (1). There is compelling evidence that FoxO3a
and FoxM1 have opposite roles in cancer: while FoxO3a behaves
like a typical tumor suppressor, FoxM1 functions as a potent
oncogene. FoxA1 is a prominent “pioneer factor” with the abil-
ity of initiating transcriptional competency and recruiting other
transcription factors to target genes. This pioneer function is of
particular importance in gene expression of endocrine-related
cancers, including breast and prostate cancers as FoxA1 is a
key cooperating factor for the nuclear hormone receptors, estro-
gen receptor-α (ER), and androgen receptor (AR) (1, 2). With
recent advances in next-generation sequencing, novel regula-
tory mechanisms, functions, and mutations have been uncovered
for these Fox proteins. The present special Research Topic of
Frontiers in Oncology is devoted to unveiling this new infor-
mation, focusing on the role and regulation of FoxA1, FoxO3a,
and FoxM1 in cancer initiation, progression, and drug resis-
tance.
Apart from cancer initiation, there is convincing evidence that
FoxM1 also has a vital role in angiogenesis, invasion, metastasis,
DNA damage repair, and the development of chemotherapeu-
tic drug resistance (3). In their review, Alvarez-Fernández and
Medema discuss the recent findings relating to these novel aspects
of FoxM1 function (4). Besides FoxM1, the oncogene myc is also
negatively regulated by FoxO3a (5, 6), and this regulation may
have a key function in the control of cellular metabolism dur-
ing cancer initiation and progression. In their mini-review, Peck
et al. describe the antagonism between FoxO3a and MYC, and its
implication in cell metabolism and cancer development (7). There
is now ample evidence that the FoxA1 gene is mutated or ampli-
fied in some breast and prostate cancers. In their mini-review,
Robinson and colleagues consider the accumulated evidence and
provide insights into the implications of FoxA1 mutations in the
context of breast and prostate cancers (8). Beyond mutations, there
are also indications that alternative splicing can produce onco-
genic versions of Fox proteins. The FoxM1 gene is made up of 10
exons, of which exon Va and VIIa are alternatively spliced, giving
rise to three distinct isoforms: FoxM1a, FoxM1b, and FoxM1c (3,
9). In their perspective article, Lam et al. present experimental
data to support their hypothesis that FoxM1b, which is overex-
pressed in cancer cells, has a greater oncogenic potential than
FoxM1c (10).
A thorough understanding of the regulation and role of these
Fox proteins in cancer will allow us to exploit them as biomark-
ers for cancer diagnosis and targets for treatment (10). Although
earlier studies have shown that nuclear translocation of FoxO3a
can lead to activation of genes important in cell cycle arrest and
cell death, recent studies in cancer patient samples have revealed
that sustained nuclear FoxO3a expression is associated with poor
prognosis (11, 12). In their commentary, Gong and Koo discuss
the implications of nuclear FoxO3a expression and examine the
molecular mechanism involved (13). The principal roles played
by FoxM1 in different aspects of cancer initiation and progres-
sion render it a prime target for pharmaceutical intervention (14).
In his perspective article, Teh summarizes the existing informa-
tion on the role of FoxM1 in cancer initiation, progression, and
drug resistance, and explores its usefulness as a biomarker for
cancer screening, prognosis, and for monitoring drug treatment
(15). The thiazole antibiotics Siomycin A and Thiostrepton have
been shown to be able to specifically target cancer cells, while
leaving normal cells alone (16). This effect depends on the abil-
ity of these antifungal agents to bind the forkhead DNA binding
domain of FoxM1 directly (17). In agreement, Gartel comments
on the role of Siomycin A and Thiostrepton in blocking the
transcriptional activity of FoxM1 and provide future perspec-
tives (18). Together, this collection of articles underscores the
importance of Fox proteins during cancer initiation and devel-
opment and proposes novel avenues for cancer diagnosis and
treatment.
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